Table 6.
Comparisons of 5- and 10-year disease-free survival and overall survival data across different tumor types vs. no adjuvant therapy.
| Tumor type | Disease-free survival: difference with adjuvant therapy vs. no therapy, % | Overall survival: difference with adjuvant therapy vs. no therapy, % | ||
|---|---|---|---|---|
| 5-year | 10-year | 5-year | 10-year | |
| Lung | ||||
| Cisplatin-based CT meta-analysis (LACE; n = 4584)192 | 5.8 | 5.4 | ||
| Median follow-up 7.5 years25 | Absolute gain 4.3 | Absolute gain 3.9 | ||
| Cisplatin-based CT (IALT, n = 1867)22 | 5 (p < 0.003) | 5 (p < 0.03) | ||
| Cisplatin + vinorelbine23 | 12 (p = 0.08) | 15 (p = 0.03) | ||
| Cisplatin + vinorelbine (ANITA)24 | 8.6 | |||
| Cisplatin-based CT (ALPI)21 | Absolute increase 4 (95% CI −1, 10) | Absolute increase 1 (95% CI −4, 7) | ||
| Colon | ||||
| 5FU/LV (IMPACT)30 | 9a | 5a | ||
| 5FU/LV (IMPACT) Stage B2 only49 | 3 (p = NS) | 2 (p = NS) | ||
| 5FU-based CT (ACCENT)156 | 7.2b (p < 0.0001) | |||
| Stage II | 5.4b (p = 0.026) | |||
| Stage III | 10.3b (p < 0.0001) | |||
| 5FU-based CT (elderly)193 | 11 (p < 0.001) | 7 (p < 0.001) | ||
| Soft tissue sarcoma | ||||
| Doxorubicin-based meta-analysis (14 trials)95 | 10 (95% CI 5, 15) | 4 (95% CI 1, 9) | ||
| Melanoma | ||||
| IFN-α2b E1684 trial (n = 287)104 | 11 (p = 0.0023) | 9 (p = 0.0237) | ||
| IFN-α2b E1690 trial (n = 642)101 HDI arm | 9 (p2 = 0.03) | −3 (p = NS) | ||
| PEG-IFN-α2b (EORTC 18991; n = 1256)108 | ||||
| All patients | 7c (p = 0.01) | 1c (p = NS) | ||
| Stage N1 only | 13c (p = 0.016) | 4c (p = NS) | ||
| Breast | ||||
| PolyCT meta-analysis116 | ||||
| <50 years | 12.5 | 12.4 | 4.7 | 7.9 |
| 50–69 years | 6.0 | 4.7 | 2.6 | 2.9 |
| Anthracycline-based CT meta-analysis117 | 8.5 | 8 | 5.1 | 5.0 |
| Standard CMF-based CT meta-analysis117 | 9.9 | 10.2 | 2.7 | 4.7 |
| Tamoxifen ~5 years meta-analysis (ER positive)116 | 11.4 | 13.6 | 3.6 | 7.9 |
CT, chemotherapy; ER, estrogen receptor; 5FU/LV, 5-fluorouracil + leucovorin; IFN-α2b, interferon-α2b; PEG-IFN-α2b, pegylated interferon-α2b.
a
3-year data. Significance testing not reported.
b
8-year data.
c
4-year data.